Capabilities · Sterile products & aseptic filling

Sterile powders for injection

A proposed service scope for sterile powder operations, connecting bulk powder handling, accurate volumetric dosing, container sealing and environmental contamination controls.

PlannedCatalogue scope

Illustrative unbranded vial neck and filling nozzle detail.
Illustrative unbranded vial neck and filling nozzle detail. It does not depict Luang Pharma's project, products or installed equipment.

Service statusPlanned

Planned.

Technical boundaries and readiness need confirmation before an activity could be presented as available.

Basis · Catalogue scope

Status
PlannedNo available service asserted
Source-plan relationship
Catalogue scopeProposed catalogue expansion
Readiness
Not establishedProduct and process evidence needed
Facility roadmap
First commercial batch target Q1 2028 · indicativeNot a service date

01 · Proposed service scope

Start with the product and its container.

Sterile powder filling is presented as a planned service domain. The exact physical properties, container presentation and powder processing route would strictly define the technical scope.

The initial Boten plan identifies liquid and lyophilised formats. Sterile powders sit outside this initial plan, so their consideration requires separate scope confirmation before any processing capability could be established.

The handling of dry powders introduces distinct flow characteristics and airborne particulate risks. Managing these properties demands different environmental containment strategies compared to conventional liquid aseptic processing.

Catalogue boundary

A planned catalogue for scoped evaluation. Inclusion does not establish installed, qualified, licensed or available capability.

02 · Presentation families

Match the route to the format.

Planned formats and their source relationship
FormatPlanning noteBasisStatus
Powder-filled vialsStandard container format proposed for potential powder dispensing evaluation.Catalogue scopePlanned
Antibiotic powdersSensitising compounds & beta-lactamsDedicated containment assessments would be necessary for sensitising compounds.Catalogue scopePlanned
Cytotoxic powder preparationsHighly potent & cytotoxic productsHighly potent materials require highly specialised containment and handling procedures.Catalogue scopePlanned

03 · Process scope for discussion

Make the sequence and its evidence visible.

01 · Process stage

Planned

Bulk powder handling

Evaluate the proposed methods for transferring sterile bulk materials into the dosing equipment.

02 · Process stage

Planned

Flow property assessment

Determine how the physical characteristics of the solid would influence accurate volumetric dispensing.

03 · Process stage

Planned

Environmental containment strategies

Define the barriers and airflow controls needed to prevent cross-contamination during active filling.

04 · Process stage

Planned

Dosing and filling

Establish the mechanical techniques required to deposit precise powder masses into individual containers.

05 · Process stage

Planned

Closure and sealing

Consider the stopper insertion and capping operations required to secure the dry product.

06 · Process stage

Planned

Weight reconciliation

Identify criteria for verifying filled masses and assessing potential dosing anomalies during evaluation.

Illustrative sequence

This is a technical discussion structure, not an operating procedure, approved process flow or representation of installed equipment.

04 · Supporting services

No service stands alone.

01PlannedCatalogue scope

Preformulation & formulation development

Material properties, formulation options and product-specific development questions.

Explore proposed scope

02PlannedCatalogue scope

Highly potent & cytotoxic products

Dedicated risk, containment and facility-segregation assessment.

Explore proposed scope

03PlannedCatalogue scope

Container-closure integrity testing

Presentation-specific integrity questions and the supporting method.

Explore proposed scope

05 · Readiness questions

A service claim needs a defined evidence base.

Powder material specifications
Exact particle size distributions, moisture limits and bulk density data.
Containment qualification status
Appropriate technical qualification of any proposed powder handling enclosures.
Dosing accuracy data
Evidence demonstrating the equipment delivers consistent fill weights for the solid.
Environmental monitoring records
Data showing the filling zone maintains the required particulate and sterility levels.
Regulatory facility permissions
Relevant permissions from the applicable authority covering dry powder operations.
Quality accountability limits
Documented agreements detailing responsibilities for material testing and batch disposition.

06 · Practical questions

Before a technical discussion.

Is this service currently available?

No. The service is Planned. This page is a scope proposal and does not establish an operating sterile-powder service.

Are sterile powders part of the initial project plan?

No. The initial plan focuses on liquid and lyophilised formulations. Sterile powder processing is a proposed extension requiring separate scope confirmation.

What information helps define the question?

Identify the proposed material, physical characteristics, container format, development stage, destination and the technical question. Confidential data should only be shared through an agreed route.

Is there a service launch quarter?

No. No service-specific quarter is established. The project-wide indicative milestones do not commit any individual service to a start date.

Does a technical discussion establish supply?

No. Feasibility, containment scope, facility permissions, equipment evidence and a technical agreement would need to be established before any supply commitment.

Back to capabilities

Professional enquiries

Discuss a defined question.

Describe the presentation, development question and destination relevant to the proposed scope. Do not infer service availability from this planning page.

Contact Luang Pharma